Purchase Order 75N98F18P00009

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $24,418.80 on November 30, 2018. The order is firm fixed price with no set-aside and carries an ultimate completion date of December 28, 2018. Place of performance is San Diego, California. The purchase order covers sequencing instruments, reagents, consumables, or bioinformatics software consistent with Illumina's core product portfolio in DNA and RNA sequencing technologies.</p>

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $13,512.96 on May 3, 2018, with an ultimate completion date of June 4, 2018. Performance takes place in San Diego, California. The order procures sequencing reagents, consumables, or related bioinformatics products. No set-aside applies.</p>

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $13,512.96 on June 29, 2018, with an ultimate completion date of July 27, 2018. Work is performed in San Diego, California. The order covers DNA and RNA sequencing instruments, reagents, consumables, or bioinformatics software. No set-aside was used.</p>

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $20,269.44 on September 21, 2017, with an ultimate completion date of October 31, 2017. Place of performance is San Diego, California. The order is firm fixed price with no set-aside applied. The purchase order procures sequencing instruments, reagents, consumables, or bioinformatics software consistent with Illumina's core product portfolio in DNA and RNA sequencing technologies.</p>

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $13,512.96 on August 10, 2017, with completion by September 29, 2017. No set-aside applied. Place of performance is San Diego, California. The order procures sequencing reagents, consumables, or related bioinformatics support—Illumina's core product line—on a firm fixed price basis.</p>

<p>The National Institute of Neurological Disorders and Stroke awarded a purchase order to Illumina, Inc. valued at $16,189.27 on July 31, 2018, with ultimate completion on July 30, 2019. The order is firm fixed price with no set-aside. Work is performed in San Diego, California. The purchase order procures sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core offerings to federal health and research agencies.</p>

The National Institute of Diabetes and Digestive and Kidney Diseases awarded a purchase order to Illumina, Inc. for $17,012.48 on April 22, 2019. The order carries a firm fixed price structure and ultimate completion date of April 21, 2020. Performance takes place in San Diego, California. The purchase order procures sequencing instruments, reagents, consumables, or bioinformatics software from Illumina's portfolio—the specific line items are not itemized in the source. No set-aside was used.

<p>The National Institutes of Health Clinical Center awarded a purchase order to Illumina, Inc. for $13,419.16 on July 25, 2018, with ultimate completion on August 8, 2018. Work is performed in San Diego, California. The order procures sequencing reagents, consumables, or related bioinformatics products on a firm fixed price basis. No set-aside category was applied.</p>

<p>The National Institutes of Health Clinical Center awarded a purchase order to Illumina, Inc. for $16,285.00 on November 17, 2017, with an ultimate completion date of November 17, 2018. Place of performance is San Diego, California. The order covers DNA and RNA sequencing instruments, reagents, consumables, or bioinformatics software. No set-aside category was used.</p>

<p>The National Institutes of Health Clinical Center awarded a purchase order to Illumina, Inc. for $10,752.18 on July 3, 2018. The order, placed under firm fixed pricing with no set-aside, calls for sequencing-related products and services. Place of performance is San Diego, California. The order carried an ultimate completion date of July 3, 2018.</p>